MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.
  • XML
    1.21 MB
  • HTML
    924.03 Kb
You must be logged in to use this functionality
Loading full text...

Full text loading...

1. Abouhamad WN, Manson M, Gibson MM, Higgins CF. 1991. Peptide transport and chemotaxis in Escherichia coli and Salmonella typhimurium: characterization of the dipeptide permease (Dpp) and the dipeptide-binding protein. Mol Microbiol 5 : 1035 1047.[PubMed][CrossRef]
2. Abraham EP. 1987. Cephalosporins 1945–1986. Drugs 34( Suppl 2) : 1 14.[PubMed][CrossRef]
3. Acebron I, Chang M, Mobashery S, Hermoso JA. 2015. The allosteric site for the nascent cell wall in penicillin-binding protein 2a: an Achilles' heel of methicillin-resistant Staphylococcus aureus. Curr Med Chem 22 : 1678 1686.[PubMed][CrossRef]
4. Achari A, Somers DO, Champness JN, Bryant PK, Rosemond J, Stammers DK. 1997. Crystal structure of the anti-bacterial sulfonamide drug target dihydropteroate synthase. Nat Struct Biol 4 : 490 497.[PubMed][CrossRef]
5. Ackermann G, Rodloff AC. 2003. Drugs of the 21st century: telithromycin (HMR 3647)—the first ketolide. J Antimicrob Chemother 51 : 497 511.[PubMed][CrossRef]
6. Adams DW, Errington J. 2009. Bacterial cell division: assembly, maintenance and disassembly of the Z ring. Nat Rev Microbiol 7 : 642 653.[PubMed][CrossRef]
7. Adnan S, Paterson DL, Lipman J, Roberts JA. 2013. Ampicillin/sulbactam: its potential use in treating infections in critically ill patients. Int J Antimicrob Agents 42 : 384 389.[PubMed][CrossRef]
8. Alexeeva S, Gadella TW Jr, Verheul J, Verhoeven GS, den Blaauwen T. 2010. Direct interactions of early and late assembling division proteins in Escherichia coli cells resolved by FRET. Mol Microbiol 77 : 384 398.[PubMed][CrossRef]
9. Allington DR, Rivey MP. 2001. Quinupristin/dalfopristin: a therapeutic review. Clin Ther 23 : 24 44.[PubMed][CrossRef]
10. American Chemical Society. 1999. Discovery and development of penicillin: international historic chemical landmark. American Chemical Society, Washington, DC. http://www.acs.org/content/acs/en/education/whatischemistry/landmarks/flemingpenicillin.html.
11. Anderson RJ, Groundwater PW, Todd A, Worsley AJ. 2012. Antibacterial Agents: Chemistry, Mode of Action, Mechanisms of Resistance and Clinical Applications. John Wiley & Sons, Ltd, Chichester, United Kingdom.
12. Andries K, Verhasselt P, Guillemont J, Gohlmann HW, Neefs JM, Winkler H, Van Gestel J, Timmerman P, Zhu M, Lee E, Williams P, de Chaffoy D, Huitric E, Hoffner S, Cambau E, Truffot-Pernot C, Lounis N, Jarlier V. 2005. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307 : 223 227.[PubMed][CrossRef]
13. Andriole VT. 2005. The quinolones: past, present, and future. Clin Infect Dis 41( Suppl 2) : S113 S119.[PubMed][CrossRef]
14. Angehrn P, Goetschi E, Gmuender H, Hebeisen P, Hennig M, Kuhn B, Luebbers T, Reindl P, Ricklin F, Schmitt-Hoffmann A. 2011. A new DNA gyrase inhibitor subclass of the cyclothialidine family based on a bicyclic dilactam-lactone scaffold. Synthesis and antibacterial properties. J Med Chem 54 : 2207 2224.[PubMed][CrossRef]
15. Arias CA, Murray BE. 2015. A new antibiotic and the evolution of resistance. N Engl J Med 372 : 1168 1170.[PubMed][CrossRef]
16. Arnison PG, Bibb MJ, Bierbaum G, Bowers AA, Bugni TS, Bulaj G, Camarero JA, Campopiano DJ, Challis GL, Clardy J, Cotter PD, Craik DJ, Dawson M, Dittmann E, Donadio S, Dorrestein PC, Entian KD, Fischbach MA, Garavelli JS, Göransson U, Gruber CW, Haft DH, Hemscheidt TK, Hertweck C, Hill C, Horswill AR, Jaspars M, Kelly WL, Klinman JP, Kuipers OP, Link AJ, Liu W, Marahiel MA, Mitchell DA, Moll GN, Moore BS, Müller R, Nair SK, Nes IF, Norris GE, Olivera BM, Onaka H, Patchett ML, Piel J, Reaney MJ, Rebuffat S, Ross RP, Sahl HG, Schmidt EW, Selsted ME, Severinov K, Shen B, Sivonen K, Smith L, Stein T, Süssmuth RD, Tagg JR, Tang GL, Truman AW, Vederas JC, Walsh CT, Walton JD, Wenzel SC, Willey JM, van der Donk WA. 2013. Ribosomally synthesized and post-translationally modified peptide natural products: overview and recommendations for a universal nomenclature. Nat Prod Rep 30 : 108 160.[PubMed][CrossRef]
17. Atherton FR, Hall MJ, Hassall CH, Lambert RW, Lloyd WJ, Ringrose PS. 1979. Phosphonopeptides as antibacterial agents: mechanism of action of alaphosphin. Antimicrob Agents Chemother 15 : 696 705.[PubMed][CrossRef]
18. Baba T, Ara T, Hasegawa M, Takai Y, Okumura Y, Baba M, Datsenko KA, Tomita M, Wanner BL, Mori H. 2006. Construction of Escherichia coli K-12 in-frame, single-gene knockout mutants: the Keio collection. Mol Syst Biol 2 : 2006.0008. 10.1038/msb4100050.[PubMed][CrossRef] http://dx.doi.org/10.1038/msb4100050
19. Babaoglu K, Qi J, Lee RE, White SW. 2004. Crystal structure of 7,8-dihydropteroate synthase from Bacillus anthracis: mechanism and novel inhibitor design. Structure 12 : 1705 1717.[PubMed][CrossRef]
20. Baca AM, Sirawaraporn R, Turley S, Sirawaraporn W, Hol WG. 2000. Crystal structure of Mycobacterium tuberculosis 7,8-dihydropteroate synthase in complex with pterin monophosphate: new insight into the enzymatic mechanism and sulfa-drug action. J Mol Biol 302 : 1193 1212.[PubMed][CrossRef]
21. Bachmann BO, Li R, Townsend CA. 1998. β-Lactam synthetase: a new biosynthetic enzyme. Proc Natl Acad Sci U S A 95 : 9082 9086.[PubMed][CrossRef]
22. Bahar AA, Ren D. 2013. Antimicrobial peptides. Pharmaceuticals (Basel) 6 : 1543 1575.[PubMed][CrossRef]
23. Bai H, Zhou Y, Hou Z, Xue X, Meng J, Luo X. 2011. Targeting bacterial RNA polymerase: promises for future antisense antibiotics development. Infect Disord Drug Targets 11 : 175 187.[PubMed][CrossRef]
24. Baldwin JE, Bradley M. 1990. Isopenicillin N synthase: mechanistic studies. Chem Rev 90 : 1079 1088.[CrossRef]
25. Baldwin JE, Adlington RM, Mitchell MB. 1995. Stereocontrolled enantiospecific synthesis of anticapsin. Tetrahedron 51 : 5193 5206.[CrossRef]
26. Balibar CJ, Howard-Jones AR, Walsh CT. 2007. Terrequinone A biosynthesis through l-tryptophan oxidation, dimerization and bisprenylation. Nat Chem Biol 3 : 584 592.[PubMed][CrossRef]
27. Balibar CJ, Vaillancourt FH, Walsh CT. 2005. Generation of d amino acid residues in assembly of arthrofactin by dual condensation/epimerization domains. Chem Biol 12 : 1189 1200.[PubMed][CrossRef]
28. Ball P. 2000. Quinolone generations: natural history or natural selection? J Antimicrob Chemother 46( Suppl T1) : 17 24.[PubMed][CrossRef]
29. Baltz R. 2007. Antimicrobials from actinomycetes: back to the tuture. Microbe 2 : 125 129.
30. Baltz RH. 2009. Daptomycin: mechanisms of action and resistance, and biosynthetic engineering. Curr Opin Chem Biol 13 : 144 151.[PubMed][CrossRef]
31. Baltz RH, Miao V, Wrigley SK. 2005. Natural products to drugs: daptomycin and related lipopeptide antibiotics. Nat Prod Rep 22 : 717 741.[PubMed][CrossRef]
32. Banik JJ, Brady SF. 2008. Cloning and characterization of new glycopeptide gene clusters found in an environmental DNA megalibrary. Proc Natl Acad Sci U S A 105 : 17273 17277.[PubMed][CrossRef]
33. Banzhaf M, van den Berg van Saparoea B, Terrak M, Fraipont C, Egan A, Philippe J, Zapun A, Breukink E, Nguyen-Distèche M, den Blaauwen T, Vollmer W. 2012. Cooperativity of peptidoglycan synthases active in bacterial cell elongation. Mol Microbiol 85 : 179 194.[PubMed][CrossRef]
34. Barb AW, Jiang L, Raetz CR, Zhou P. 2007a. Structure of the deacetylase LpxC bound to the antibiotic CHIR-090: time-dependent inhibition and specificity in ligand binding. Proc Natl Acad Sci U S A 104 : 18433 18438.[CrossRef]
35. Barb AW, Leavy TM, Robins LI, Guan Z, Six DA, Zhou P, Hangauer MJ, Bertozzi CR, Raetz CR. 2009. Uridine-based inhibitors as new leads for antibiotics targeting Escherichia coli LpxC. Biochemistry 48 : 3068 3077.[PubMed][CrossRef]
36. Barb AW, McClerren AL, Snehelatha K, Reynolds CM, Zhou P, Raetz CR. 2007b. Inhibition of lipid A biosynthesis as the primary mechanism of CHIR-090 antibiotic activity in Escherichia coli. Biochemistry 46 : 3793 3802.[CrossRef]
37. Barry AL, Thornsberry C, Jones RN, Gavan TL. 1985. Aztreonam: antibacterial activity, beta-lactamase stability, and interpretive standards and quality control guidelines for disk-diffusion susceptibility tests. Rev Infect Dis 7( Suppl 4) : S594 S604.[PubMed][CrossRef]
38. Batt SM, Jabeen T, Bhowruth V, Quill L, Lund PA, Eggeling L, Alderwick LJ, Fütterer K, Besra GS. 2012. Structural basis of inhibition of Mycobacterium tuberculosis DprE1 by benzothiazinone inhibitors. Proc Natl Acad Sci U S A 109 : 11354 11359.[PubMed][CrossRef]
39. Bauer A, Bronstrup M. 2014. Industrial natural product chemistry for drug discovery and development. Nat Prod Rep 31 : 35 60.[PubMed][CrossRef]
40. Bauer JD, King RW, Brady SF. 2010. Utahmycins A and B, azaquinones produced by an environmental DNA clone. J Nat Prod 73 : 976 979.[PubMed][CrossRef]
41. Baum EZ, Crespo-Carbone SM, Klinger A, Foleno BD, Turchi I, Macielag M, Bush K. 2007. A MurF inhibitor that disrupts cell wall biosynthesis in Escherichia coli. Antimicrob Agents Chemother 51 : 4420 4426.[PubMed][CrossRef]
42. Baumann S, Herrmann J, Raju R, Steinmetz H, Mohr KI, Hüttel S, Harmrolfs K, Stadler M, Müller R. 2014. Cystobactamids: myxobacterial topoisomerase inhibitors exhibiting potent antibacterial activity. Angew Chem Int Ed Engl 53 : 14605 14609.[PubMed][CrossRef]
43. Bax BD, Chan PF, Eggleston DS, Fosberry A, Gentry DR, Gorrec F, Giordano I, Hann MM, Hennessy A, Hibbs M, Huang J, Jones E, Jones J, Brown KK, Lewis CJ, May EW, Saunders MR, Singh O, Spitzfaden CE, Shen C, Shillings A, Theobald AJ, Wohlkonig A, Pearson ND, Gwynn MN. 2010. Type IIA topoisomerase inhibition by a new class of antibacterial agents. Nature 466 : 935 940.[PubMed][CrossRef]
44. Bayer AS, Schneider T, Sahl HG. 2013. Mechanisms of daptomycin resistance in Staphylococcus aureus: role of the cell membrane and cell wall. Ann N Y Acad Sci 1277 : 139 158.[PubMed][CrossRef]
45. Bayer E, Gugel KH, Hägele K, Hagenmaier H, Jessipow S, König WA, Zähner H. 1972. Metabolic products of microorganisms. 98. Phosphinothricin and phosphinothricyl-alanyl-analine. Helv Chim Acta 55 : 224 239. (In German.)[PubMed][CrossRef]
46. Beld J, Sonnenschein EC, Vickery CR, Noel JP, Burkart MD. 2014. The phosphopantetheinyl transferases: catalysis of a post-translational modification crucial for life. Nat Prod Rep 31 : 61 108.[PubMed][CrossRef]
47. Bennett BC, Wan Q, Ahmad MF, Langan P, Dealwis CG. 2009. X-ray structure of the ternary MTX.NADPH complex of the anthrax dihydrofolate reductase: a pharmacophore for dual-site inhibitor design. J Struct Biol 166 : 162 171.[PubMed][CrossRef]
48. Benson TE, Prince DB, Mutchler VT, Curry KA, Ho AM, Sarver RW, Hagadorn JC, Choi GH, Garlick RL. 2002. X-ray crystal structure of Staphylococcus aureus FemA. Structure 10 : 1107 1115.[PubMed][CrossRef]
49. Benson TE, Walsh CT, Hogle JM. 1997. X-ray crystal structures of the S229A mutant and wild-type MurB in the presence of the substrate enolpyruvyl- UDP- N-acetylglucosamine at 1.8-Å resolution. Biochemistry 36 : 806 811.[PubMed][CrossRef]
50. Bentley SD, Chater KF, Cerdeño-Tárraga AM, Challis GL, Thomson NR, James KD, Harris DE, Quail MA, Kieser H, Harper D, Bateman A, Brown S, Chandra G, Chen CW, Collins M, Cronin A, Fraser A, Goble A, Hidalgo J, Hornsby T, Howarth S, Huang CH, Kieser T, Larke L, Murphy L, Oliver K, O'Neil S, Rabbinowitsch E, Rajandream MA, Rutherford K, Rutter S, Seeger K, Saunders D, Sharp S, Squares R, Squares S, Taylor K, Warren T, Wietzorrek A, Woodward J, Barrell BG, Parkhill J, Hopwood DA. 2002. Complete genome sequence of the model actinomycete Streptomyces coelicolor A3(2). Nature 417 : 141 147.[PubMed][CrossRef]
51. Benveniste R, Davies J. 1973. Aminoglycoside antibiotic-inactivating enzymes in actinomycetes similar to those present in clinical isolates of antibiotic-resistant bacteria. Proc Natl Acad Sci U S A 70 : 2276 2280.[PubMed][CrossRef]
52. Berdy J. 2005. Bioactive microbial metabolites. J Antibiot (Tokyo) 58 : 1 26.[PubMed][CrossRef]
53. Berdy J. 2012. Thoughts and facts about antibiotics: where we are now and where we are heading. J Antibiot (Tokyo) 65 : 385 395.[PubMed][CrossRef]
54. Bermingham A, Derrick JP. 2002. The folic acid biosynthesis pathway in bacteria: evaluation of potential for antibacterial drug discovery. Bioessays 24 : 637 648.[PubMed][CrossRef]
55. Biarrotte-Sorin S, Maillard AP, Delettré J, Sougakoff W, Arthur M, Mayer C. 2004. Crystal structures of Weissella viridescens FemX and its complex with UDP-MurNAc-pentapeptide: insights into FemABX family substrates recognition. Structure 12 : 257 267.[PubMed][CrossRef]
56. Biggins JB, Ternei MA, Brady SF. 2012. Malleilactone, a polyketide synthase-derived virulence factor encoded by the cryptic secondary metabolome of Burkholderia pseudomallei group pathogens. J Am Chem Soc 134 : 13192 13195.[PubMed][CrossRef]
57. Bihelovic F, Karadzic I, Matovic R, Saicic RN. 2013. Total synthesis and biological evaluation of (–)-atrop-abyssomicin C. Org Biomol Chem 11 : 5413 5424.[PubMed][CrossRef]
58. Bihelovic F, Saicic RN. 2012. Total synthesis of (–)-atrop-abyssomicin C. Angew Chem Int Ed Engl 51 : 5687 5691.[PubMed][CrossRef]
59. Biliouris K, Daoutidis P, Kaznessis YN. 2011. Stochastic simulations of the tetracycline operon. BMC Syst Biol 5 : 9. 10.1186/1752-0509-5-9.[PubMed][CrossRef] http://dx.doi.org/10.1186/1752-0509-5-9
60. Birnbaum J, Kahan FM, Kropp H, MacDonald JS. 1985. Carbapenems, a new class of beta-lactam antibiotics. Discovery and development of imipenem/cilastatin. Am J Med 78 : 3 21.[PubMed][CrossRef]
61. Bischoff D, Pelzer S, Höltzel A, Nicholson GJ, Stockert S, Wohlleben W, Jung G, Süssmuth RD. 2001. The biosynthesis of vancomycin-type glycopeptide antibiotics—new insights into the cyclization steps. Angew Chem Int Ed Engl 40 : 1693 1696.[PubMed][CrossRef]
62. Bister B, Bischoff D, Ströbele M, Riedlinger J, Reicke A, Wolter F, Bull AT, Zähner H, Fiedler HP, Süssmuth RD. 2004. Abyssomicin C-A polycyclic antibiotic from a marine Verrucosispora strain as an inhibitor of the p-aminobenzoic acid/tetrahydrofolate biosynthesis pathway. Angew Chem Int Ed Engl 43 : 2574 2576.[PubMed][CrossRef]
63. Blair JM, Webber MA, Baylay AJ, Ogbolu DO, Piddock LJ. 2015. Molecular mechanisms of antibiotic resistance. Nat Rev Microbiol 13 : 42 51.[PubMed][CrossRef]
64. Blanco D, Perez-Herran E, Cacho M, Ballell L, Castro J, González Del Río R, Lavandera JL, Remuiñán MJ, Richards C, Rullas J, Vázquez-Muñiz MJ, Woldu E, Zapatero-González MC, Angulo-Barturen I, Mendoza A, Barros D. 2015. Mycobacterium tuberculosis gyrase inhibitors as a new class of antitubercular drugs. Antimicrob Agents Chemother 59 : 1868 1875.[PubMed][CrossRef]
65. Blázquez B, Llarrull LI, Luque-Ortega JR, Alfonso C, Boggess B, Mobashery S. 2014. Regulation of the expression of the β-lactam antibiotic-resistance determinants in methicillin-resistant Staphylococcus aureus (MRSA). Biochemistry 53 : 1548 1550.[CrossRef]
66. Blin K, Medema MH, Kazempour D, Fischbach MA, Breitling R, Takano E, Weber T. 2013. antiSMASH 2.0—a versatile platform for genome mining of secondary metabolite producers. Nucleic Acids Res 41 (Web Server issue) : W204 W212.[PubMed][CrossRef]
67. Bock C, Lengauer T. 2012. Managing drug resistance in cancer: lessons from HIV therapy. Nat Rev Cancer 12 : 494 501.[PubMed][CrossRef]
68. Boddy CN, Schneider TL, Hotta K, Walsh CT, Khosla C. 2003. Epothilone C macrolactonization and hydrolysis are catalyzed by the isolated thioesterase domain of epothilone polyketide synthase. J Am Chem Soc 125 : 3428 3429.[PubMed][CrossRef]
69. Boger DL. 2001. Vancomycin, teicoplanin, and ramoplanin: synthetic and mechanistic studies. Med Res Rev 21 : 356 381.[PubMed][CrossRef]
70. Bohn C, Bouloc P. 1998. The Escherichia coli cmlA gene encodes the multidrug efflux pump Cmr/MdfA and is responsible for isopropyl-β- d-thiogalactopyranoside exclusion and spectinomycin sensitivity. J Bacteriol 180 : 6072 6075.[PubMed]
71. Bok JW, Balajee SA, Marr KA, Andes D, Nielsen KF, Frisvad JC, Keller NP. 2005. LaeA, a regulator of morphogenetic fungal virulence factors. Eukaryot Cell 4 : 1574 1582.[PubMed][CrossRef]
72. Bok JW, Keller NP. 2004. LaeA, a regulator of secondary metabolism in Aspergillus spp. Eukaryot Cell 3 : 527 535.[PubMed][CrossRef]
73. Bonnemain C, Raynaud C, Réglier-Poupet H, Dubail I, Frehel C, Lety MA, Berche P, Charbit A. 2004. Differential roles of multiple signal peptidases in the virulence of Listeria monocytogenes. Mol Microbiol 51 : 1251 1266.[PubMed][CrossRef]
74. Bonnet R. 2004. Growing group of extended-spectrum β-lactamases: the CTX-M enzymes. Antimicrob Agents Chemother 48 : 1 14.[PubMed][CrossRef]
75. Borbulevych O, Kumarasiri M, Wilson B, Llarrull LI, Lee M, Hesek D, Shi Q, Peng J, Baker BM, Mobashery S. 2011. Lysine N ζ-decarboxylation switch and activation of the β-lactam sensor domain of BlaR1 protein of methicillin-resistant Staphylococcus aureus. J Biol Chem 286 : 31466 31472.[PubMed][CrossRef]
76. Borel JF, Kis ZL. 1991. The discovery and development of cyclosporine (Sandimmune). Transplant Proc 23 : 1867 1874.[PubMed]
77. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J. 2009. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 48 : 1 12.[PubMed][CrossRef]
78. Bouley R, Kumarasiri M, Peng Z, Otero LH, Song W, Suckow MA, Schroeder VA, Wolter WR, Lastochkin E, Antunes NT, Pi H, Vakulenko S, Hermoso JA, Chang M, Mobashery S. 2015. Discovery of antibiotic ( E)-3-(3-carboxyphenyl)-2-(4-cyanostyryl)quinazolin-4(3 H)-one. J Am Chem Soc 137 : 1738 1741.[PubMed][CrossRef]
79. Bourne CR. 2014. Utility of the biosynthetic folate pathway for targets in antimicrobial discovery. Antibiotics 3 : 1 28.[CrossRef]
80. Bower JM, Eto DS, Mulvey MA. 2005. Covert operations of uropathogenic Escherichia coli within the urinary tract. Traffic 6 : 18 31.[PubMed][CrossRef]
81. Bowers AA, Walsh CT, Acker MG. 2010. Genetic interception and structural characterization of thiopeptide cyclization precursors from Bacillus cereus. J Am Chem Soc 132 : 12182 12184.[PubMed][CrossRef]
82. Braun V, Hantke K. 1974. Biochemistry of bacterial cell envelopes. Annu Rev Biochem 43 : 89 121.[PubMed][CrossRef]
83. Breazeale SD, Ribeiro AA, McClerren AL, Raetz CR. 2005. A formyltransferase required for polymyxin resistance in Escherichia coli and the modification of lipid A with 4-amino-4-deoxy- l-arabinose. Identification and function of UDP-4-deoxy-4-formamido- l-arabinose. J Biol Chem 280 : 14154 14167.[PubMed][CrossRef]
84. Brennan PJ. 2003. Structure, function, and biogenesis of the cell wall of Mycobacterium tuberculosis. Tuberculosis (Edinb) 83 : 91 97.[PubMed][CrossRef]
85. Breukink E, de Kruijff B. 2006. Lipid II as a target for antibiotics. Nat Rev Drug Discov 5 : 321 332.[PubMed][CrossRef]
86. Brickner S. 1996. Oxazolidinone antibacterial agents. Curr Pharm Des 2 : 175 194.
87. Brock TD, Madigan MT, Martinko JM, Parker J. 1994. Biology of Microorganisms, 7th ed. Prentice-Hall, Inc, Englewood Cliffs, NJ.
88. Brogden KA. 2005. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat Rev Microbiol 3 : 238 250.[PubMed][CrossRef]
89. Brown ED, Vivas EI, Walsh CT, Kolter R. 1995. MurA (MurZ), the enzyme that catalyzes the first committed step in peptidoglycan biosynthesis, is essential in Escherichia coli. J Bacteriol 177 : 4194 4197.[PubMed]
90. Brown MF, Reilly U, Abramite JA, Arcari JT, Oliver R, Barham RA, Che Y, Chen JM, Collantes EM, Chung SW, Desbonnet C, Doty J, Doroski M, Engtrakul JJ, Harris TM, Huband M, Knafels JD, Leach KL, Liu S, Marfat A, Marra A, McElroy E, Melnick M, Menard CA, Montgomery JI, Mullins L, Noe MC, O'Donnell J, Penzien J, Plummer MS, Price LM, Shanmugasundaram V, Thoma C, Uccello DP, Warmus JS, Wishka DG. 2012. Potent inhibitors of LpxC for the treatment of Gram-negative infections. J Med Chem 55 : 914 923.[PubMed][CrossRef]
91. Brown RC, Hopps HC. 1973. Staining of bacteria in tissue sections: a reliable gram stain method. Am J Clin Pathol 60 : 234 240.[PubMed]
92. Brown RP, Aplin RT, Schofield CJ. 1996. Inhibition of TEM-2 β-lactamase from Escherichia coli by clavulanic acid: observation of intermediates by electrospray ionization mass spectrometry. Biochemistry 35 : 12421 12432.[PubMed][CrossRef]
93. Brubaker JD, Myers AG. 2007. A practical, enantioselective synthetic route to a key precursor to the tetracycline antibiotics. Org Lett 9 : 3523 3525.[PubMed][CrossRef]
94. Bryk R, Gold B, Venugopal A, Singh J, Samy R, Pupek K, Cao H, Popescu C, Gurney M, Hotha S, Cherian J, Rhee K, Ly L, Converse PJ, Ehrt S, Vandal O, Jiang X, Schneider J, Lin G, Nathan C. 2008. Selective killing of nonreplicating mycobacteria. Cell Host Microbe 3 : 137 145.[PubMed][CrossRef]
95. Bugg TD, Dutka-Malen S, Arthur M, Courvalin P, Walsh CT. 1991a. Identification of vancomycin resistance protein VanA as a d-alanine: d-alanine ligase of altered substrate specificity. Biochemistry 30 : 2017 2021.[CrossRef]
96. Bugg TD, Wright GD, Dutka-Malen S, Arthur M, Courvalin P, Walsh CT. 1991b. Molecular basis for vancomycin resistance in Enterococcus faecium BM4147: biosynthesis of a depsipeptide peptidoglycan precursor by vancomycin resistance proteins VanH and VanA. Biochemistry 30 : 10408 10415.[CrossRef]
97. Bull AT, Stach JE. 2007. Marine actinobacteria: new opportunities for natural product search and discovery. Trends Microbiol 15 : 491 499.[PubMed][CrossRef]
98. Bulychev A, Mobashery S. 1999. Class C β-lactamases operate at the diffusion limit for turnover of their preferred cephalosporin substrates. Antimicrob Agents Chemother 43 : 1743 1746.[PubMed]
99. Bunkoczi G, Vertesy L, Sheldrick GM. 2005. Structure of the lipopeptide antibiotic tsushimycin. Acta Crystallogr D Biol Crystallogr 61 : 1160 1164.[PubMed][CrossRef]
100. Burman W, Dooley KE, Nuermberger EL,. 2011. The rifamycins: renewed interest in an old drug class, pp 18 24. In Donald PR, Helden PD (ed), Antituberculosis Chemotherapy, vol 40. Karger, Basel, Switzerland.
101. Burzlaff NI, Rutledge PJ, Clifton IJ, Hensgens CM, Pickford M, Adlington RM, Roach PL, Baldwin JE. 1999. The reaction cycle of isopenicillin N synthase observed by X-ray diffraction. Nature 401 : 721 724.[PubMed][CrossRef]
102. Bush K, Courvalin P, Dantas G, Davies J, Eisenstein B, Huovinen P, Jacoby GA, Kishony R, Kreiswirth BN, Kutter E, Lerner SA, Levy S, Lewis K, Lomovskaya O, Miller JH, Mobashery S, Piddock LJ, Projan S, Thomas CM, Tomasz A, Tulkens PM, Walsh TR, Watson JD, Witkowski J, Witte W, Wright G, Yeh P, Zgurskaya HI. 2011. Tackling antibiotic resistance. Nat Rev Microbiol 9 : 894 896.[PubMed][CrossRef]
103. Bush K, Jacoby GA. 2010. Updated functional classification of β-lactamases. Antimicrob Agents Chemother 54 : 969 976.[PubMed][CrossRef]
104. Bush K, Jacoby GA, Medeiros AA. 1995. A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 39 : 1211 1233.[PubMed][CrossRef]
105. Bush K, Mobashery S. 1998. How beta-lactamases have driven pharmaceutical drug discovery. From mechanistic knowledge to clinical circumvention. Adv Exp Med Biol 456 : 71 98.[PubMed][CrossRef]
106. Busiek KK, Eraso JM, Wang Y, Margolin W. 2012. The early divisome protein FtsA interacts directly through its 1c subdomain with the cytoplasmic domain of the late divisome protein FtsN. J Bacteriol 194 : 1989 2000.[PubMed][CrossRef]
107. Butler MS, Blaskovich MA, Cooper MA. 2013. Antibiotics in the clinical pipeline in 2013. J Antibiot (Tokyo) 66 : 571 591.[PubMed][CrossRef]
108. Butler MS, Cooper MA. 2011. Antibiotics in the clinical pipeline in 2011. J Antibiot (Tokyo) 64 : 413 425.[PubMed][CrossRef]
109. Butler MS, Hansford KA, Blaskovich MA, Halai R, Cooper MA. 2014. Glycopeptide antibiotics: back to the future. J Antibiot (Tokyo) 67 : 631 644.[PubMed][CrossRef]
110. Butler SM, Festa RA, Pearce MJ, Darwin KH. 2006. Self-compartmentalized bacterial proteases and pathogenesis. Mol Microbiol 60 : 553 562.[PubMed][CrossRef]
111. Cabeen MT, Jacobs-Wagner C. 2005. Bacterial cell shape. Nat Rev Microbiol 3 : 601 610.[PubMed][CrossRef]
112. Campbell EA, Pavlova O, Zenkin N, Leon F, Irschik H, Jansen R, Severinov K, Darst SA. 2005. Structural, functional, and genetic analysis of sorangicin inhibition of bacterial RNA polymerase. EMBO J 24 : 674 682.[PubMed][CrossRef]
113. Campbell J, Singh AK, Santa Maria JP Jr, Kim Y, Brown S, Swoboda JG, Mylonakis E, Wilkinson BJ, Walker S. 2011. Synthetic lethal compound combinations reveal a fundamental connection between wall teichoic acid and peptidoglycan biosyntheses in Staphylococcus aureus. ACS Chem Biol 6 : 106 116.[PubMed][CrossRef]
114. Cane DE, Walsh CT. 1999. The parallel and convergent universes of polyketide synthases and nonribosomal peptide synthetases. Chem Biol 6 : R319 R325.[PubMed][CrossRef]
115. Cane DE, Walsh CT, Khosla C. 1998. Harnessing the biosynthetic code: combinations, permutations, and mutations. Science 282 : 63 68.[PubMed][CrossRef]
116. Canton R, Coque TM. 2006. The CTX-M β-lactamase pandemic. Curr Opin Microbiol 9 : 466 475.[PubMed][CrossRef]
117. Canton R, Gonzalez-Alba JM, Galan JC. 2012. CTX-M enzymes: origin and diffusion. Front Microbiol 3 : 110. 10.3389/fmicb.2012.00110.[PubMed][CrossRef] http://dx.doi.org/10.3389/fmicb.2012.00110
118. Cantu C III, Huang W, Palzkill T. 1997. Cephalosporin substrate specificity determinants of TEM-1 β-lactamase. J Biol Chem 272 : 29144 29150.[PubMed][CrossRef]
119. Carfi A, Pares S, Duée E, Galleni M, Duez C, Frère JM, Dideberg O. 1995. The 3-D structure of a zinc metallo-β-lactamase from Bacillus cereus reveals a new type of protein fold. EMBO J 14 : 4914 4921.[PubMed]
120. Carreras C, Santi D. 1995. The catalytic mechanism and structure of thymidylate synthase. Annu Rev Biochem 64 : 721 762.[PubMed][CrossRef]
121. Castiglione F, Lazzarini A, Carrano L, Corti E, Ciciliato I, Gastaldo L, Candiani P, Losi D, Marinelli F, Selva E, Parenti F. 2008. Determining the structure and mode of action of microbisporicin, a potent lantibiotic active against multiresistant pathogens. Chem Biol 15 : 22 31.[PubMed][CrossRef]
122. Cavalleri B, Pagani H, Volpe G, Selva E, Parenti F. 1984. A-16686, a new antibiotic from Actinoplanes. I. Fermentation, isolation and preliminary physico-chemical characteristics. J Antibiot (Tokyo) 37 : 309 317.[PubMed][CrossRef]
123. Centers for Disease Control and Prevention. 2013. Antibiotic Resistance Threats in the United States, 2013. Centers for Disease Control and Prevention, Atlanta, GA. http://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf.
124. Cetinkaya Y, Falk P, Mayhall CG. 2000. Vancomycin-resistant enterococci. Clin Microbiol Rev 13 : 686 707.[PubMed][CrossRef]
125. Chairatana P, Nolan EM. 2014. Molecular basis for self-assembly of a human host-defense peptide that entraps bacterial pathogens. J Am Chem Soc 136 : 13267 13276.[PubMed][CrossRef]
126. Chait R, Shrestha S, Shah AK, Michel JB, Kishony R. 2010. A differential drug screen for compounds that select against antibiotic resistance. PLoS One 5 : e15179. 10.1371/journal.pone.0015179.[PubMed][CrossRef] http://dx.doi.org/10.1371/journal.pone.0015179
127. Chait R, Vetsigian K, Kishony R. 2012. What counters antibiotic resistance in nature? Nat Chem Biol 8 : 2 5.[CrossRef]
128. Chan YY, Bian HS, Tan TM, Mattmann ME, Geske GD, Igarashi J, Hatano T, Suga H, Blackwell HE, Chua KL. 2007. Control of quorum sensing by a Burkholderia pseudomallei multidrug efflux pump. J Bacteriol 189 : 4320 4324.[PubMed][CrossRef]
129. Chang FY, Ternei MA, Calle PY, Brady SF. 2015. Targeted metagenomics: finding rare tryptophan dimer natural products in the environment. J Am Chem Soc 137 : 6044 6052.[PubMed][CrossRef]
130. Chang WC, Dey M, Liu P, Mansoorabadi SO, Moon SJ, Zhao ZK, Drennan CL, Liu HW. 2013. Mechanistic studies of an unprecedented enzyme-catalysed 1,2-phosphono-migration reaction. Nature 496 : 114 118.[PubMed][CrossRef]
131. Chang WC, Guo Y, Wang C, Butch SE, Rosenzweig AC, Boal AK, Krebs C, Bollinger JM Jr. 2014. Mechanism of the C5 stereoinversion reaction in the biosynthesis of carbapenem antibiotics. Science 343 : 1140 1144.[PubMed][CrossRef]
132. Charest MG, Lerner CD, Brubaker JD, Siegel DR, Myers AG. 2005a. A convergent enantioselective route to structurally diverse 6-deoxytetracycline antibiotics. Science 308 : 395 398.[CrossRef]
133. Charest MG, Siegel DR, Myers AG. 2005b. Synthesis of (–)-tetracycline. J Am Chem Soc 127 : 8292 8293.[CrossRef]
134. Chater KF. 2006. Streptomyces inside-out: a new perspective on the bacteria that provide us with antibiotics. Philos Trans R Soc Lond B Biol Sci 361 : 761 768.[PubMed][CrossRef]
135. Chater KF, Horinouchi S. 2003. Signalling early developmental events in two highly diverged Streptomyces species. Mol Microbiol 48 : 9 15.[PubMed][CrossRef]
136. Chen DZ, Patel DV, Hackbarth CJ, Wang W, Dreyer G, Young DC, Margolis PS, Wu C, Ni ZJ, Trias J, White RJ, Yuan Z. 2000a. Actinonin, a naturally occurring antibacterial agent, is a potent deformylase inhibitor. Biochemistry 39 : 1256 1262.[CrossRef]
137. Chen H, Thomas MG, Hubbard BK, Losey HC, Walsh CT, Burkart MD. 2000b. Deoxysugars in glycopeptide antibiotics: enzymatic synthesis of TDP- l-epivancosamine in chloroeremomycin biosynthesis. Proc Natl Acad Sci U S A 97 : 11942 11947.[CrossRef]
138. Chen H, Thomas MG, O'Connor SE, Hubbard BK, Burkart MD, Walsh CT. 2001. Aminoacyl- S-enzyme intermediates in β-hydroxylations and α,β-desaturations of amino acids in peptide antibiotics. Biochemistry 40 : 11651 11659.[PubMed][CrossRef]
139. Chen MW, Lohkamp B, Schnell R, Lescar J, Schneider G. 2013. Substrate channel flexibility in MurB accommodates two distinct substrates. PLoS One 8 : e66936. 10.1371/journal.pone.0066936.[PubMed][CrossRef] http://dx.doi.org/10.1371/journal.pone.0066936
140. Chen Y, Yin M, Horsman GP, Huang S, Shen B. 2010. Manipulation of pathway regulation in Streptomyces globisporus for overproduction of the enediyne antitumor antibiotic C-1027. J Antibiot (Tokyo) 63 : 482 485.[PubMed][CrossRef]
141. Cheung J, Beasley FC, Liu S, Lajoie GA, Heinrichs DE. 2009. Molecular characterization of staphyloferrin B biosynthesis in Staphylococcus aureus. Mol Microbiol 74 : 594 608.[PubMed][CrossRef]
142. Chiang YM, Lee KH, Sanchez JF, Keller NP, Wang CC. 2009. Unlocking fungal cryptic natural products. Nat Prod Commun 4 : 1505 1510.[PubMed]